{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:24:00Z","timestamp":1792481040204,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Dispersible and immediate-release fixed-dose combinations (FDC) of abacavir, dolutegravir, and lamivudine are priority first-line antiretroviral therapy (ART) in children with HIV-1 (CWHIV). We report safety, efficacy and tolerability of these regimens through 48 weeks of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>IMPAACT 2019 was a phase I\/II, international, multisite, open-label, noncomparative study of dispersible and immediate-release FDC abacavir\/dolutegravir\/lamivudine (ABC\/DTG\/3TC) in participants with HIV-1 &lt;12 years of age weighing 6 to &lt;40\u2009kg. At entry, participants were ART-naive or ART-experienced and virally suppressed on stable ART for \u22656 months. Participants received weight-banded dosing and enrolled across 5 weight bands in parallel. Follow-up visits were completed at weeks 1, 4, 12, 24, 36 and 48.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-seven participants were enrolled; 2 participants withdrew due to poor drug tolerability. Fifty-four of 55 participants on the study at week 48 remained on the study drug. All 54 participants who remained on study drug through week 48 had viral loads of &lt;200 copies\/mL. CD4-lymphocyte counts remained stable with age over 48 weeks. Mean change (95% confidence interval) in body mass index Z-scores was 0.4 (0.2\u20130.6). Nine study drug-related adverse events were reported. One drug-induced liver injury attributed to abacavir and dolutegravir led to the permanent discontinuation of the study drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Dispersible FDC ABC\/DTG\/3TC is the first dispersible dolutegravir-containing single tablet regimen for CWHIV. Dispersible- and immediate-release ABC\/DTG\/3TC was observed to be generally safe, effective and well-tolerated in CWHIV through 48 weeks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004859","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:03:56Z","timestamp":1748538236000},"page":"777-784","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir\/Dolutegravir\/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-9139","authenticated-orcid":false,"given":"Helena","family":"Rabie","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Science, University of Stellenbosch, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-1004","authenticated-orcid":false,"given":"Dwight E.","family":"Yin","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Ward","sequence":"additional","affiliation":[{"name":"Frontier Science Foundation, Brookline, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-4383","authenticated-orcid":false,"given":"Yasha","family":"Rani","sequence":"additional","affiliation":[{"name":"Frontier Science Foundation, Brookline, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5266-3657","authenticated-orcid":false,"given":"Lauren","family":"Ziemba","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-8699","authenticated-orcid":false,"given":"Kristina M.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-0974","authenticated-orcid":false,"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[{"name":"PHPT-Chiangrai Prachanukroh Hospital, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-9637","authenticated-orcid":false,"given":"Gaerolwe R.","family":"Masheto","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3709-6547","authenticated-orcid":false,"given":"Haseena","family":"Cassim","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-0658","authenticated-orcid":false,"given":"Jaime G.","family":"Deville","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine, UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7549-8300","authenticated-orcid":false,"given":"Ponego L.","family":"Ponatshego","sequence":"additional","affiliation":[{"name":"Clinical Trails Unit, Botswana Harvard AIDS Institute Partnership, Molepole, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-2016","authenticated-orcid":false,"given":"Faeezah","family":"Patel","sequence":"additional","affiliation":[{"name":"Wits RHI, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0246-8187","authenticated-orcid":false,"given":"Linda","family":"Aurpibul","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun L.","family":"Barnabas","sequence":"additional","affiliation":[{"name":"Famcru, University of Stellenbosch, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-3311","authenticated-orcid":false,"given":"Iris","family":"Mustich","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1787-9966","authenticated-orcid":false,"given":"Anne","family":"Coletti","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Heckman","sequence":"additional","affiliation":[{"name":"Frontier Science, Amherst, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Krotje","sequence":"additional","affiliation":[{"name":"Frontier Science, Amherst, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Townley","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Moye","sequence":"additional","affiliation":[{"name":"Maternal and Pediatric Infectious Disease Branch, National Institute of Child Health and Human Development, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Majji","sequence":"additional","affiliation":[{"name":"Maternal and Pediatric Infectious Disease Branch, National Institute of Child Health and Human Development, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease, University of Alabama-Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease, University of Alabama-Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Chandasana","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H.","family":"Brothers","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"Flynn","sequence":"additional","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the IMPAACT 2019 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3018(22)00101-1","article-title":"Advancing the prevention and treatment of HIV in children: priorities for research and development.","volume":"9","author":"Penazzato","year":"2022","journal-title":"Lancet HIV"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(22)00044-3","article-title":"Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.","volume":"9","author":"Ruel","year":"2022","journal-title":"Lancet HIV"},{"key":"R6-20250723"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","article-title":"Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens.","volume":"94","author":"Clay","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3018(23)00107-8","article-title":"Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.","volume":"10","author":"Brooks","year":"2023","journal-title":"Lancet HIV"},{"key":"R10-20250723"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R12-20250723","article-title":"Child growth standards."},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2003.07.003","article-title":"Lymphocyte subsets in healthy children from birth through 18 years of age: the pediatric AIDS clinical trials group P1009 study.","volume":"112","author":"Shearer","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0000000000001244","article-title":"Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children.","volume":"30","author":"\u00c1sbj\u00f6rnsd\u00f3ttir","year":"2016","journal-title":"AIDS"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clinre.2013.02.008","article-title":"Hepatoxicity of new antiretrovirals: a systematic review.","volume":"37","author":"Surgers","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bjid.2016.03.002","article-title":"Abacavir-induced liver toxicity.","volume":"20","author":"Pezzani","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"ofx122","DOI":"10.1093\/ofid\/ofx122","article-title":"Abacavir\/Dolutegravir\/Lamivudine (Triumeq)-induced liver toxicity in a human immunodeficiency virus-infected patient.","volume":"4","author":"Christensen","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/QAD.0000000000002191","article-title":"Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature.","volume":"33","author":"Nhean","year":"2019","journal-title":"AIDS"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/QAI.0000000000002470","article-title":"Brief report: subclinical kidney dysfunction in HIV-infected children: a cross-sectional study.","volume":"85","author":"Kruthika","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ekir.2020.09.001","article-title":"HIV-associated CKDs in children and adolescents.","volume":"5","author":"Beng","year":"2020","journal-title":"Kidney Int Rep"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2431-13-75","article-title":"Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study.","volume":"13","author":"Dondo","year":"2013","journal-title":"BMC Pediatr"},{"key":"R23-20250723","doi-asserted-by":"crossref","first-page":"e25899","DOI":"10.1002\/jia2.25899","article-title":"Weight gain during the dolutegravir transition in the African cohort study.","volume":"25","author":"Esber","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy.","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R25-20250723","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/QAI.0000000000002661","article-title":"Genetic associations with weight gain among South Africans who initiated dolutegravir-containing and tenofovir-containing regimens.","volume":"87","author":"Cindi","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-20250723","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/cid\/ciad107","article-title":"Changes in body mass index with longer-term integrase inhibitor use: a longitudinal analysis of data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).","volume":"76","author":"Kileel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R27-20250723","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jpids\/piaa052","article-title":"Excessive weight gain associated with dolutegravir initiation in a 10-year-old female with perinatally acquired human immunodeficiency virus: a case report and review of the literature.","volume":"10","author":"Li","year":"2021","journal-title":"J. Pediatric Infect Dis Soc"},{"key":"R28-20250723","article-title":"Obesity and overweight key facts."},{"key":"R29-20250723","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/INF.0000000000003904","article-title":"Decreased hepatic steatosis in South African adolescents with perinatal HIV switching to dolutegravir-containing regimens.","volume":"42","author":"Rose","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20250723","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2352-4642(23)00164-5","article-title":"Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.","volume":"7","author":"Turkova","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R31-20250723","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/cid\/ciad656","article-title":"Twice-daily dosing of dolutegravir in infants on rifampicin treatment: a pharmacokinetic substudy of the EMPIRICAL trial.","volume":"78","author":"Jacobs","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R32-20250723","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2352-3018(22)00160-6","article-title":"Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.","volume":"9","author":"Turkova","year":"2022","journal-title":"Lancet HIV"},{"key":"R33-20250723","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s40121-024-01008-y","article-title":"Population pharmacokinetic modeling of abacavir\/dolutegravir\/lamivudine to support a fixed-dose combination in children with HIV-1.","volume":"13","author":"Chandasana","year":"2024","journal-title":"Infect Dis Ther"},{"key":"R34-20250723","first-page":"583","article-title":"A single once daily ABC\/DTG\/3TC tablet predicts safe and effective exposures in children 3 to <6kg. [CROI Abstract 944] in special issue: abstracts from the CROI 2024 conference on retroviruses and opportunistic infections.","volume":"32","author":"Chandasana","year":"2024","journal-title":"Top Antivir Med"},{"key":"R35-20250723","article-title":"HIV mid-year market memo; June 2023."},{"key":"R36-20250723"},{"key":"R37-20250723"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T20:00:19Z","timestamp":1753300819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004859","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}